NEW YORK, April 7, 2014 /PRNewswire/ --
Today, Analysts Review released its analysts' notes regarding
Dr. Reddy's Laboratories Ltd. (NYSE: RDY), ICON plc (NASDAQ: ICLR),
Endocyte, Inc. (NASDAQ: ECYT), BioScrip Inc. (NASDAQ: BIOS), and
DepoMed Inc. (NASDAQ: DEPO). Private wealth members receive these
notes ahead of publication. To reserve complementary membership,
limited openings are available at:
http://www.AnalystsReview.com/register
--
Dr. Reddy's Laboratories Ltd. Analyst Notes
On March 27, 2014, Dr. Reddy's
Laboratories Ltd. (Dr. Reddy's) announced the launch of Amlodipine
Besylate and Atorvastatin Calcium Tablets, a therapeutic equivalent
generic version of CADUET tablets, in the US market on March 17, 2014, following its U.S. FDA approval.
Dr. Reddy's Amlodipine Besylate and Atorvastatin Calcium Tablets
are available in bottle counts of 30 and 90. According to IMS
Health, the CADUET® tablets brand and generic had U.S. sales of
approximately $163 Million MAT for
the most recent twelve months ended January
2014. The full analyst notes on Dr. Reddy's Laboratories
Ltd. are available to download free of charge at:
http://www.AnalystsReview.com/04072014/RDY/report.pdf
--
ICON plc Analyst Notes
On March 31, 2014, ICON plc,
(ICON) announced that it has agreed to acquire Aptiv Solutions for
$143.5 million. According to the
Company, Aptiv Solutions is a recognized leader in the design and
execution of adaptive clinical trials for pharmaceutical and
biotech customers. Commenting on the acquisition, Dr. Nuala Murphy, President, ICON Clinical Research
Services, said, "ICON's market-leading innovation is helping our
customers to reduce the time and cost of drug development. We are
achieving this through the combination of our industry expertise
and enabling technologies such as ICONIK and Firecrest. Aptiv
Solutions' adaptive trial capabilities will further differentiate
and enhance our services to help our customers identify the most
promising drug candidates earlier. Their presence in Japan will also broaden our existing
capabilities in this market." The full analyst notes on ICON plc
are available to download free of charge at:
http://www.AnalystsReview.com/04072014/ICLR/report.pdf
--
Endocyte, Inc. Analyst Notes
On April 2, 2014, Endocyte, Inc.
(Endocyte) announced the closing of its underwritten public
offering of approximately 5.2 million shares of its common stock at
a price to the public of $21.00 per
share. This includes the full exercise by the underwriters of their
option to purchase c. 0.7 million additional shares. The Company
informed that it has received net proceeds of approximately
$101.8 million from the offering. The
full analyst notes on Endocyte, Inc. are available to download free
of charge at:
http://www.AnalystsReview.com/04072014/ECYT/report.pdf
--
BioScrip Inc. Analyst Notes
On April 1, 2014, BioScrip, Inc.
(BioScrip) announced that it has completed its previously announced
sale of substantially all of its Home Health Business, the
Deaconess HomeCare to LHC Group, Inc. in a deal valued at
approximately $60 million. "With the
completion of the Home Health transaction, we now have additional
financial flexibility to continue building on BioScrip's solid
foundation in home infusion services," said Rick Smith, President and CEO of BioScrip. "We
continue to position BioScrip as a leader in the home infusion
industry. We look forward to optimizing the value of our assets
while maintaining our reputation for clinical excellence." BioScrip
intends to use the net proceeds to pay down a part of its
outstanding debt. The full analyst notes on BioScrip Inc. are
available to download free of charge at:
http://www.AnalystsReview.com/04072014/BIOS/report.pdf
--
DepoMed Inc. Analyst Notes
On March 12, 2014, Depomed, Inc.
(Depomed) reported its Q4 2013 and full-year 2013 financial
results. For the quarter, revenues came in at $40.6 million, compared to $26.6 million in Q4 2012. Net income totaled
$41.8 million, or $0.72 per share, compared with a net loss of
$3.7 million, or $0.07 per share, in Q4 2012. For full year 2013,
total revenues were $134.2 million
compared to $90.8 million in 2012.
Net income stood at $43.3 million, or
$0.75 per share, compared to a net
loss of $29.8 million, or
$0.53 per share, in 2012. Net income
for the quarter and full year 2013 included a $39 million income tax benefit related to the
reversal of the valuation allowance on its deferred tax assets The
Company anticipates full-year 2014 revenue to range from
$200 million to $215 million and GAAP
EPS to range between $0.21 and $0.36
per share. The full analyst notes on DepoMed Inc. are available to
download free of charge at:
http://www.AnalystsReview.com/04072014/DEPO/report.pdf
--
About Analysts Review
We provide our members with a simple and reliable way to leverage
our economy of scale. Most investors do not have time to track all
publicly traded companies, much less perform an in-depth review and
analysis of the complexities contained in each situation. That's
where Analysts Review comes in. We provide a single unified
platform for investors' to hear about what matters. Situation
alerts, moving events, and upcoming opportunities.
--
=============
EDITOR NOTES:
- This is not company news. We are an independent source and our
views do not reflect the companies mentioned.
- Information in this release is fact checked and produced on a
best efforts basis and reviewed by Nidhi Vatsal, a CFA
charterholder. However, we are only human and are prone to make
mistakes. If you notice any errors or omissions, please notify us
below.
- This information is submitted as a net-positive to companies
mentioned, to increase awareness for mentioned companies to our
subscriber base and the investing public.
- If you wish to have your company covered in more detail by our
team, or wish to learn more about our services, please contact us
at pubco [at] AnalystsReview.com.
- For any urgent concerns or inquiries, please contact us
at compliance [at] AnalystsReview.com.
- Are you a public company? Would you like to see similar
coverage on your company? Send us a full investors' package to
research [at] AnalystsReview.com for consideration.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort
basis. This document, article or report is prepared and authored by
Analysts Review. An outsourced research services provider
represented by Nidhi Vatsal, CFA, has only reviewed the information
provided by Analysts Review in this article or report according to
the Procedures outlined by Analysts Review. Analysts Review is not
entitled to veto or interfere in the application of such procedures
by the outsourced provider to the articles, documents or reports,
as the case may be.
NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to
the accuracy or completeness or fitness for a purpose (investment
or otherwise), of the information provided in this document. This
information is not to be construed as personal financial advice.
Readers are encouraged to consult their personal financial advisor
before making any decisions to buy, sell or hold any securities
mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be
occasioned at the time of printing of this document or any error,
mistake or shortcoming. No liability is accepted by Analysts Review
whatsoever for any direct, indirect or consequential loss arising
from the use of this document. Analysts Review expressly disclaims
any fiduciary responsibility or liability for any consequences,
financial or otherwise arising from any reliance placed on the
information in this document. Analysts Review does not (1)
guarantee the accuracy, timeliness, completeness or correct
sequencing of the information, or (2) warrant any results from use
of the information. The included information is subject to change
without notice.
CFA® and Chartered Financial Analyst® are registered trademarks
owned by CFA Institute.
http://AnalystsReview.com
SOURCE Analysts Review